Thursday, November 26, 2009


I have been asked about OFAR (combined oxaliplatin, fludarabine, cytarabine and rituximab) There is one paper at ASH from MDACC on OFAR used as salvage therapy in patients with del 17p. There were no CRs among the 28 patients, but the overall response rate was 39%. The median overall survival was 16 months.

There is a published Phase 1/2 trial of OFAR in JCO, also from MDACC, on the treatment of CLL patients either refractory to fludarabine of with Richter's syndrome (RS). The overall response rates were 50% in RS and 33% in fludarabine-refractory CLL. The median response duration was 10 months.

The dose of oxaliplatin used in OFAR is far less than is used in FOLFOX regimens for colon cancer. At the lower dose the peripheral neuropathy should not be a problem.

No comments: